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Negative cooperativity across b1-adrenoceptor homodimers
provides insights into the nature of the secondary
low-afﬁnity CGP 12177 b1-adrenoceptor binding
conformation
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ABSTRACT At the b1-adrenoceptor, CGP 12177 po-
tently antagonizes agonist responses at the primary high-
afﬁnity catecholamine conformation while also exerting
agonist effects of its own through a secondary low-afﬁnity
conformation. A recent mutagenesis study identiﬁed
transmembrane region (TM)4 of the b1-adrenoceptor as
key for this low-afﬁnity conformation.Others suggested
that TM4 has a role inb1-adrenoceptor oligomerization.
Here, assessment of the dissociation rate of a ﬂuorescent
analog of CGP 12177 [bordiﬂuoropyrromethane-tetra-
methylrhodamine-(6)CGP12177 (BODIPY-TMR-CGP)]
at the human b1-adrenoceptor expressed in Chinese
hamster ovary cells revealed negative cooperative
interactions between 2 distinct b1-adrenoceptor con-
formations. The dissociation rate of 3 nM BODIPY-
TMR-CGP was 0.09 6 0.01 min21 in the absence of
competitor ligands, and this was enhanced 2.2- and 2.1-
fold in the presence of 1 mM CGP 12177 and 1 mM
propranolol, respectively. These effects on the BODIPY-
TMR-CGP dissociation rate were markedly enhanced in
b1-adrenoceptor homodimers constrainedbybimolecular
ﬂuorescence complementation (9.8- and9.9-fold for 1mM
CGP 12177 and 1 mM propranolol, respectively) and
abolished in b1-adrenoceptors containing TM4 muta-
tions vital for the second conformation pharmacology.
This study suggests that negative cooperativity across
a b1-adrenoceptor homodimer may be responsible for
generating the low-afﬁnity pharmacology of the second-
ary b1-adrenoceptor conformation.—Gherbi, K., May,
L. T., Baker, J. G., Briddon, S. J., Hill, S. J. Negative
cooperativity acrossb1-adrenoceptor homodimers pro-
vides insights into the nature of the secondary low-
afﬁnity CGP 12177 b1-adrenoceptor binding confor-
mation. FASEB J. 29, 2859–2871 (2015). www.fasebj.org
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THE b1-ADRENOCEPTOR HAS BEEN REPORTED to exist in 2
active conformations (1–6), although the nature of the
secondary b1-adrenoceptor conformation has been the
subject of speculation for many years (7–11). The endoge-
nous ligands adrenaline and noradrenaline exhibit their
agonist effects through theorthosteric catecholamine siteof
the b1-adrenoceptor. These agonist responses are antago-
nized by b-blockers such as CGP 20712A, CGP 12177, and
propranolol with high afﬁnity (6, 12–14). However, CGP
12177 (15) was also found to exert partial agonist effects at
100-fold higher concentrations than were needed to an-
tagonizecatecholamine-mediatedagonist responses (4, 12).
According to classic receptor theory, the EC50 of a partial
agonist is expected to be similar to its binding afﬁnity. The
discrepancy between these 2 values for CGP 12177 and also
other b-adrenoceptor ligands, such as pindolol, led to the
classiﬁcation of nonconventional b-adrenoceptor agonists
(16). Furthermore, the CGP 12177 agonist effect appeared
resistant tob-blocker antagonismat concentrationsnormally
sufﬁcient to block catecholamine-mediated agonist effects
(4, 6, 12, 14, 17). As such, the afﬁnities of a range of b-
adrenoceptor antagonists have been reported to be $1 or-
der ofmagnitude lowerwhen inhibiting responsesmediated
by CGP 12177 at the b1-adrenoceptor compared with those
mediated by catecholamines in both animal and human tis-
sue preparations (10, 14, 18). It is noteworthy that the use of
recombinant cell systems and cardiac tissue isolated fromb2-
andb1-/b2-adrenoceptor knockoutmice clearly showed that
the b1-adrenoceptor alone was responsible for the observed
CGP 12177 pharmacology (1, 3, 4). This led to the proposal
that thereare2active conformationsof theb1-adrenoceptor:
a primary high-afﬁnity endogenous catecholamine site and
a secondary low-afﬁnity CGP 12177 site (1, 4).
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Site-directed mutagenesis has been used in previous
studies to investigate the nature of the secondary low-afﬁnity
b1-adrenoceptor conformation (7, 11). Initial work sug-
gested some overlap of the 2 proposed b1-adrenoceptor
binding conformations (7). However, more recently, Baker
et al. (11) demonstrated that residues L195 and W199 in
transmembrane domain (TM)4 are essential for the sec-
ondaryb1-adrenoceptor conformation(11).Furthermore,
TM4may have a role in oligomerization (19), because the
formation of b1-adrenoceptor homodimers has been
reported previously (20–22), and an important interface
for this appears to be between TM4 and TM5 (19).
Ab1-adrenoceptor homodimer complexwould possess 2
structurally identical orthosteric b1-adrenoceptor sites, to
which ligands would be expected to bind with similar af-
ﬁnities. However, negative cooperative interactions be-
tween the 2 orthosteric b1-adrenoceptor binding sites may
provideanexplanationof the lower afﬁnity observed for the
secondary b1-adrenoceptor protomer, if indeed this occurs
as a dimer (23). Negative cooperativity across a homodimer
interface has previously been described for the human A3
adenosine receptor (23). In this example, negative coop-
erativity was demonstrated in single living cells by following
the impact of orthosteric unlabeled ligands binding to
one protomer of an A3-homodimer on the dissociation of
a ﬂuorescently labeled agonist (which was enhanced) from
the orthosteric site of the other A3-receptor protomer (23).
We previously showed that the ﬂuorescent CGP 12177 an-
alog bordiﬂuoropyrromethane-tetramethylrhodamine-(6)
CGP 12177 (BODIPY-TMR-CGP) can be used to label both
conformations of the b1-adrenoceptor (24). In this study,
we used this ﬂuorescent CGP 12177 analog to investigate
the potential for allosteric interactions across a homodimer
interface of the b1-adrenoceptor using kinetic measure-
ments of BODIPY-TMR-CGP binding in single living cells.
MATERIALS AND METHODS
Materials
Cell culture plastics were purchased from Thermo Fisher Scien-
tiﬁc (Loughborough, United Kingdom), and cell culture
reagents were from Sigma-Aldrich (Gillingham, United King-
dom) except for fetal calf serum, which was obtained from PAA
Laboratories (Pasching, Austria). Lipofectamine 2000 trans-
fection reagent and Opti-MEM medium were from Invitrogen
(Paisley, United Kingdom), and SNAP-Surface 488 was from
New England Biolabs (Ipswich, MA, USA). BODIPY-TMR-CGP
was from Molecular Probes (Leiden, The Netherlands), and un-
labeled CGP 12177 and propranolol were from Tocris Cookson
(Avonmouth, Bristol, United Kingdom). All other reagents were
from Sigma Chemicals (Poole, United Kingdom).
Cell culture
Chinese hamster ovary (CHO)-K1 cells were used for all transient
transfections. CHO-K1 cells stably expressing the secreted pla-
cental alkaline phosphatase reporter gene under the transcrip-
tional control of a 6-cAMP response element promoter (CHO-CS
cells) were used as a control, as appropriate. CHO-CS cell lines
either expressing human wild-type b1-adrenoceptors (CHO-b1
cells; 1147 fmol/mg protein) (6) or human b1-adrenoceptors
containing 11 amino acid mutations (G177V, L178I, V179I,
C180L, T181M, A184I, I185V, A187G, V189T, L195Q, and
W199Y that convert TM4 to the equivalent residues in the b2-
adrenoceptor; CHO-b1TM4 cells) (11) were used. CHO-K1,
CHO-CS, CHO-b1, and CHO-b1TM4 cells were grown at 37°C
in CHO growth medium [DMEM/Ham’s nutrient mixture F12
containing 10%(v/v) fetal calf serumand2mML-glutamine] in
a humidiﬁed 5% CO2/95% air atmosphere.
Generation of b1-adrenoceptor constructs
The b1-yellow ﬂuorescent protein (YFP)N and b1-YFPC receptor
constructs were generated by fusing either the N-terminal frag-
mentof YFP(YFPN; aminoacids 1–155)or theC-terminal fragment
of YFP (YFPC; amino acids 156–239) to the C-terminal end of the
full-length wild-type human b1-adrenoceptor. The SNAP-b1 con-
structwasgeneratedby fusing theSNAP-tag(NewEnglandBiolabs,
Ipswich, MA, USA) to the N-terminal end of the wild-type human
b1-adrenoceptor.TheD138Amutation(7)was introduced into the
b1-YFPC and the SNAP-b1 sequence using the QuikChange site-
directedmutagenesis kit (Agilent Technologies, Cheshire, United
Kingdom). All sequences were conﬁrmed by DNA sequencing. All
receptor constructs were subcloned into pcDNA3.1 vectors.
SNAP-tag labeling and confocal imaging
Confocal microscopy was performed using a Zeiss LSM710 laser
scanningmicroscope with a340 1.3NAoil immersion lens. CHO-
K1 cells were grown to 70% conﬂuence in 8-well Labtek borosili-
catechambered-coverglasses (NalgeneNuncInternational, Fisher
Scientiﬁc) and transiently transfected with SNAP-b1 or SNAP-
b1D138A recombinant DNA using Lipofectamine 2000 and Opti-
MEMmedium according to the manufacturer’s instructions. The
next day, a 1 mM concentration of the benzyl-guanine labeled
SNAP-tag substrate SNAP-Surface 488 (BG-488) was prepared
in fresh cell culture medium, added to these cells, and incubated
in the dark for 30 min (room temperature). The cells then
were washed twice in imaging buffer (147 mM NaCl, 24 mM
KCl, 1.3 mM CaCl2, 1 mM MgSO4, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, 2 mM sodium pyruvate, 1.43 mM
NaHCO3 4.5 mM D-glucose, pH 7.4). After this, 3 nM BODIPY-
TMR-CGP was added to the cells in the dark for 10 min (room
temperature), after which the cells were imaged immediately
(10243 1024pixels, averaging at 4 frames, pinhole diameter 1 airy
unit); 561 nm diode and 488 nm argon lasers were used to excite
BODIPY-TMR-CGP and BG-488, respectively. A variable spectral
detection system was used to capture emission at 565–605 and
495–535 nm, respectively. Confocal settings for laser power, offset,
and gain were kept constant throughout each experiment set.
BODIPY-TMR-CGP kinetic studies using the confocal
perfusion system
BODIPY-TMR-CGP association and dissociation kinetics
Live cell ﬂuorescence imaging was performed on the Zeiss
LSM510 laser scanning confocal microscope using a Zeiss Plan-
Neoﬂuar340 1.3NAoil-immersionobjective in conjunctionwith
a temperature-controlled (37°C) perfusion system to allow the
visualization and quantiﬁcation of BODIPY-TMR-CGP dissocia-
tion kinetics under inﬁnite dilution (ID) conditions in single liv-
ing cells (25). Kinetic experiments were performed as described
byMay et al. (25). In brief, cells were grown tonear conﬂuence on
32 mm glass coverslips in 6-well plates 1 d prior to experimen-
tation. On the day of experimentation, the coverslip was placed
into a tightly closed imaging chamber on a heated (37°C) mi-
croscope stage, where it was connected to tubes to facilitate the
ﬂow of imaging buffer through the imaging chamber in the ab-
sence and presence of BODIPY-TMR-CGP and/or unlabeled
ligands at a constant ﬂow rate of$4 ml/min.
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For association and dissociation kinetic experiments of
10–100nMBODIPY-TMR-CGP inCHO-b1 andCHO-CScells, the
cells were exposed to imaging buffer only (30 s baseline ﬂuores-
cence recording), thenBODIPY-TMR-CGP(4.5min association),
and followed again by imaging buffer only (4.5min dissociation).
BODIPY-TMR-CGPwas excitedusing a543nmhelium-neon laser
with emission collected through a 565 nm long-passﬁlter every 3 s
throughout each experiment (512 3 512 pixels, averaging at 2
frames). The pinhole diameter (1 airy unit), laser power (2%),
offset, and gain remained constant between the 3 BODIPY-TMR-
CGP concentrations and the 2 cell lines used. Membrane-
associated BODIPY-TMR-CGP ﬂuorescence was measured by
drawing regions of interest (ROIs) around the membranes of 10
single cells of each imaged coverslip, and changes in the average
pixel intensity values for each ROI over time were analyzed to
obtain association and dissociation rates for each experiment.
Measuring the inﬂuence of unlabeled ligands on the
BODIPY-TMR-CGP dissociation rate
Live cell ﬂuorescence imaging using 3 nMBODIPY-TMR-CGPwas
performed on the Zeiss LSM710 laser scanning confocal micro-
scope using a Zeiss Plan-Neoﬂuar 340 1.3 NA oil-immersion ob-
jective in conjunction with a perfusion system as described above
for the Zeiss LSM510 laser scanning confocal microscope. For as-
sociationanddissociationkineticexperimentsusing3nMBODIPY-
TMR-CGP inCHO-b1 andCHO-CS cells, the cells were exposed to
imaging buffer only (30 s baseline ﬂuorescence recording), then
BODIPY-TMR-CGP (4 min association), and followed again by
imaging buffer only (4 min dissociation). Inﬂuences of unlabeled
ligandsontheBODIPY-TMR-CGPdissociationrate inCHO-b1 cells
were determined by perfusion of imaging buffer (30 s baseline
read), 3 nM BODIPY-TMR-CGP (4 min association), and imaging
buffer (4 min dissociation) in the absence or presence of CGP
12177 (0.01–10 mM) or propranolol (0.1–10 mM).
In experiments using CHO-b1TM4 cells, the cells were ﬁrst
exposed to 3 nMBODIPY-TMR-CGP for 3.5 min in a 6-well plate
prior toplacing thecoverslip into the imagingchamber toachieve
a signiﬁcant but low level of labeling of the receptor.Once placed
onto themicroscope stage, the cells were perfused with BODIPY-
TMR-CGP (30 s baseline), before perfusing imaging buffer in the
absence or presence of 1 mM CGP 12177 or 1 mM propranolol
(dissociation).
In bimolecular ﬂuorescence complementation (BiFC)
experiments, CHO-K1 cells were seeded onto coverslips on
day 1 and transiently transfected with YFPN- and YFPC-tagged
b1-adrenoceptor recombinant DNA (750 ng total) using
Lipofectamine 2000 and Opti-MEM medium according to the
manufacturer’s instructions on day 2. The following day, the
transfection medium was removed and replaced with fresh
CHO growth medium, before the cells were placed back into
the cell culture incubator (37°C, 5%CO2/95%air atmosphere).
After;6 h, the cells weremoved into a 30°C incubator overnight
(5% CO2/95% air atmosphere) to allow the maturation of the
ﬂuorophore following correct protein folding (26). On day 4,
the cells were used for experimentation, and the dissociation of
3 nM BODIPY-TMR-CGP in the absence and presence of un-
labeled ligands was determined as described above.
BODIPY-TMR-CGP and YFP (when used) were excited
using a 561 nm diode and 488 argon laser, respectively, every
2 s throughout each experiment (5123 512 pixels, averaging
at 2 frames). A variable spectral detection system was used to
capture BODIPY-TMR-CGP and YFP emission at 565–605
and 495–535 nm, respectively. The pinhole diameter (1 airy
unit) and laser power (5%) remained constant between all
experiments, but the gain and offset were adjusted for each
experiment for optimal detection of 3 nM BODIPY-TMR-
CGP, and kinetic data were expressed in percentage ﬂuo-
rescent intensity to allow data to be grouped and compared.
ROIs were drawn around the membranes of 3–10 single cells of
each imaged coverslip, and changes in average pixel intensity
values for each ROI over time were analyzed to obtain BODIPY-
TMR-CGP dissociation rates for each experiment. In BiFC
experiments, membrane-associated BODIPY-TMR-CGP ﬂuores-
cencewasmeasuredbydrawingROIs aroundmembranesof cells
that were identiﬁed to express BiFC-constrained homodimers
by examination of the YFP ﬂuorescence.
Data analysis
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA)
was used to ﬁt all data presented in this study. Association kinetic
data wereﬁtted using the followingmonoexponential association
equation:
Y ¼ Y0 þ ðPlateau2Y0Þ

12 e2konobs3 t

(1)
whereY0 is the level of BODIPY-TMR-CGP binding at time t = 0
(i.e., baseline ﬂuorescence), Plateau is the level of BODIPY-
TMR-CGP binding at inﬁnite time, and konobs is the rate of
observed association.
BODIPY-TMR-CGPﬂuorescence intensitiesmeasured at time
t4.5min in CHO-b1 cells and CHO-CS cells were plotted against
the BODIPY-TMR-CGP concentrations used and ﬁtted to a 1-site
total binding saturation equation (Eq. 2) or a nonspeciﬁc bind-
ing linear regression equation (Eq. 3), respectively
Total binding ¼ BMAX3 ½BðKD þ ½BÞ þM 3 ½B þ C (2)
NS binding ¼ M 3 ½B þ C (3)
where BMAX is the maximum speciﬁc BODIPY-TMR-CGP bind-
ing, [B] is the BODIPY-TMR-CGP concentration, KD is the
BODIPY-TMR-CGP concentration that achieves 50% speciﬁc
binding,Mdenotes the slopeof the linear regression component,
and C is the background ﬂuorescence intensity.
The dissociation kinetic data were analyzed using the follow-
ing monoexponential decay equation, if nonspeciﬁc binding
of ,10% of total binding was observed for a given BODIPY-
TMR-CGP concentration
Y ¼ ðY02PlateauÞ3 e2koff 3 t þ Plateau (4)
where Y0, Plateau, and t are the same as deﬁned above with t0
representing the start of dissociation in Y0 (i.e., the binding of
BODIPY-TMR-CGP at time zero). The koff is the dissociation
rate of BODIPY-TMR-CGP. Where a level of nonspeciﬁc bind-
ing.10%of total bindingwas observed, the dissociation kinetic
data were ﬁtted to a 2-phase exponential decay function
Y ¼ Plateauþ Spanfast3 e2koffðfastÞ3 t þ Spanslow3 e2koffðslowÞ3 t
(5)
where Plateau and t are as deﬁned above, and Spanfast and Spanslow
represent theproportionofY0-Plateauaccountedforby the fast (koff
(fast)) and slow (koff(slow)) dissociation rate, respectively. Within this
analysis, koff(fast) and Plateau was constrained to the average rate of
dissociation and the average Plateau (in %) reached by BODIPY-
TMR-CGP in control CHO-CS cells (i.e., cell not expressing the
receptor of interest to determine the nonspeciﬁc BODIPY-TMR-
CGP binding component). Equation 6 was then used to calculate
the association rate constants (kon) using the konobs and koff(slow)
determined above for each BODIPY-TMR-CGP concentration [B]
kon ¼

konobs2 koffðslowÞ

½B (6)
The negative logarithms of the equilibrium dissociation constant
(pKD) were obtained using the above determined kinetic
parameters in the following equation:
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pKD ¼2log

koffðslowÞ
kon

(7)
Experiments investigating the kinetic parameters of 3 nM
BODIPY-TMR-CGP binding to CHO-b1 cells were analyzed
using a global ﬁt of its association (Eq. 8a) and dissociation
traces (Eq. 8b)
Y ¼ BMAX3 ð33 10
29Þ
ð33 1029Þ þ KD 3

12 e2½ð33 1029Þ3 konþkoff 3 t

þNS
(8a)
Y ¼ BMAX3 ð33 10
29Þ
ð33 1029Þ þ KD 3

12 e2½ð33 1029Þ3 konþkoff 3T ðIDÞ

3 e2koff 3 ðt 2T ðIDÞÞ þNS
(8b)
where BMAX is the maximum speciﬁc BODIPY-TMR-CGP bind-
ing, KD is the BODIPY-TMR-CGP concentration that achieves
50%speciﬁc binding,NS isnonspeciﬁc binding,T(ID) is the time
at which inﬁnite dilution was commenced, and kon, koff, and t are
as described above.
Concentration-dependent cooperative effects of un-
labeled ligands CGP 12177 and propranolol on the dissoci-
ation rate of 3 nMBODIPY-TMR-CGPwereﬁt to the following
equation:
BODIPY 2TMR2CGP dissociation rate ¼ ðEMAX3 ½BÞ½B þ KDðsite 2Þ
(9)
where EMAX is the maximal increase in BODIPY-TMR-CGP dis-
sociation rate, [B] is the concentration of unlabeled ligand, and
KD(site 2) is the concentrationof theunlabeled ligand that achieves
50% binding to a secondary binding site that exerts cooperative
effects on the BODIPY-TMR-CGP dissociation from the primary
binding site. Ameasure of cooperativity between 2 binding sites is
provided by the cooperativity factora, which was calculated using
the following equation:
a ¼ KDðsite 1Þ
KDðsite 2Þ
(10)
where KD(site 1) is the equilibrium dissociation constant of a given
ligand for the primary (site 1) binding site of an unbound re-
ceptor, andKD(site 2) is theequilibriumdissociationconstantof the
same ligand for the secondary (site 2) binding site of a ligand-
bound (at site 1) receptor.
All data are represented as means6 SEM from n separate experi-
ments. Statistical analysis was performed where appropriate and as
detailed in the text, with P, 0.05 reﬂecting statistical signiﬁcance.
RESULTS
Kinetic parameters of BODIPY-TMR-CGP at the
human b1-adrenoceptor
The association and dissociation of 10, 30, and 100 nM
BODIPY-TMR-CGP at the human b1-adrenoceptor were
examined inCHO-b1 andCHO-CScells todetermine total
and nonspeciﬁc binding levels, respectively. Using the
same microscope settings for all BODIPY-TMR-CGP con-
centrations in both cell lines allowed direct comparison
of ﬂuorescence intensities and thus BODIPY-TMR-CGP
binding levels (Fig. 1). The ﬂuorescence intensity levels in-
creased with increasing BODIPY-TMR-CGP concentrations
in bothCHO-b1 andCHO-CS cells; however, thenonspeciﬁc
cell membrane-associated ﬂuorescence intensity in CHO-CS
cells was markedly lower than the total binding cell
membrane-associated ﬂuorescence intensity measured in
CHO-b1 cells (Fig. 2A, B). A plot of the binding levels against
BODIPY-TMR-CGP concentration was best described by
a saturable and linear component following 4.5 min associa-
tion in CHO-b1 cells (Fig. 2C). In contrast, the increase in
BODIPY-TMR-CGP binding levels with increasing concen-
trationofﬂuorescent label inCHO-CScellswasbestdescribed
by a linear relationship (Fig. 2D), which is characteristic of
Figure 1. Concentration-dependent increase of
BODIPY-TMR-CGP binding levels in CHO-b1
and CHO-CS cells. Confocal images of 10, 30,
and 100 nM BODIPY-TMR-CGP (BOD-CGP)
binding levels following 4.5 min association
measured in CHO-b1 and CHO-CS cells. The
microscope settings were kept constant for the
recordings of ﬂuorescence intensities of all 3
BODIPY-TMR-CGP concentrations in both
CHO-b1 and CHO-CS cells to allow for direct
comparison of the BODIPY-TMR-CGP binding
levels. Images are representatives of a total of 5,
6, and 4 separate experiments (for 10, 30, and
100 nM BODIPY-TMR-CGP, respectively) using
CHO-b1 cells, and 3, 6, and 3 separate experi-
ments (for 10, 30, and 100 nM BODIPY-TMR-
CGP, respectively) using CHO-CS cells. Scale
bars, 50 mm.
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nonspeciﬁc binding components. Interestingly the non-
speciﬁc binding component appeared smaller in the cells
expressing the human b1-adrenoceptor (Fig. 2C).
The association and dissociation traces obtained in
CHO-CS could only be accurately analyzed for 30 and
100 nM BODIPY-TMR-CGP, and revealed rapid observed
association (konobs) and dissociation (koff) rates (Table 1),
which provides further evidence that BODIPY-TMR-CGP
binding interactions in CHO-CS were nonspeciﬁc (27).
The association of 10, 30, and 100 nM BODIPY-TMR-
CGP in CHO-b1 cells wasmonoexponential, and a plateau
of BODIPY-TMR-CGP binding was reached following
4.5-min exposure of CHO-b1 cells to 30 and 100 nM, but
not 10 nM, BODIPY-TMR-CGP (Fig. 3C). The concentra-
tiondependenceof theobservedassociation ratesof 10, 30,
and 100 nM BODIPY-TMR-CGP at the b1-adrenoceptor
was clearly seen for the normalized groupdata (Fig. 3A), as
well as the individual cell data (Fig. 3C). The derived ob-
servedassociation rates (konobs) increased from0.636 0.08
(n = 5) to 1.646 0.08 (n = 6) and 3.086 0.11min21 (n = 4)
for 10, 30, and 100 nM BODIPY-TMR-CGP, respectively.
The dissociation of 10 nM BODIPY-TMR-CGP was
also monoexponential yielding a dissociation rate of
0.09 6 0.01 min21 (n = 5). By contrast, 2 dissociation
components, a fast (koff(fast)) anda slow(koff(slow)) component,
were detected in the dissociation of 30 and 100 nMBODIPY-
TMR-CGP. The rate of the fast dissociating component
was comparable to the dissociation rate determined in
CHO-CS cells and was thus deﬁned as a nonspeciﬁc com-
ponent, which was constrained to the average dissociation
rateobtained inCHO-CScells (2.47min21) in theﬁttingof
the 2-component dissociation rates. The slow disso-
ciation component determined for 30 and 100 nM
BODIPY-TMR-CGP inCHO-b1 cells was 0.096 0.01 (n = 6)
and 0.14 6 0.02 min21 (n = 4), respectively. Interestingly,
the dissociation rate determined for 100 nM BODIPY-
TMR-CGP was signiﬁcantly faster than the rate determined
for 10 and 30 nM BODIPY-TMR-CGP (P , 0.05, 1-way
ANOVA followed by Tukey’s multiple comparisons test;
Table 1). We have previously shown that 100 nM BODIPY-
Figure 2. Characterization of BODIPY-TMR-
CGP binding properties in CHO-b1 and CHO-
CS cells. The ﬂuorescence intensity of 10, 30,
and 100 nM BODIPY-TMR-CGP (BOD-CGP)
was monitored every 3 s (shown for every 6 s
for better visualization) in (A) CHO-b1 and (B)
CHO-CS cells to determine association rates
duringBODIPY-TMR-CGPperfusion(ﬁrst4.5min),
anddissociation ratesduringperfusionof imaging
buffer only (subsequent 4.5 min). The ﬂuores-
cence intensity values measured in (C) CHO-b1
and (D) CHO-CS cells following 4.5 min
association of 10, 30, and 100 nM BODIPY-
TMR-CGPwereplottedagainst thecorresponding
BODIPY-TMR-CGP concentration and highlight
the saturable binding of BODIPY-TMR-CGP to
CHO-b1 but not CHO-CS cells at the concen-
trations used. Data shown aremeans6 SEM of 3–6
separate experiments per BODIPY-TMR-CGP
concentration in each cell line. Each experi-
mental replicate reﬂects the average ﬂuores-
cent intensity of the plasma membrane of 10
cells. Summary data and statistical analysis are
provided in Table 1.
TABLE 1. Kinetic parameters of 10, 30, and 100 nM BODIPY-TMR-CGP at CHO-b1 and CHO-CS cells
BODIPY-TMR-CGP
konobs
(min21)
koff(fast)
(min21)
koff(slow)
(min21)
kon
(3107 M21×min21) pKD n
CHO-CS (nM)
10 NA NA 3
30 1.40 6 0.26 2.46 6 0.48 6
100 1.62 6 0.13 2.47 6 0.13 3
CHO-b1 (nM)
10 0.63 6 0.08 NA 0.10 6 0.01 5.29 6 0.79 8.71 6 0.05 5
30 1.64 6 0.08* 2.47 0.09 6 0.01 5.17 6 0.28 8.77 6 0.08 6
100 3.08 6 0.11*,# 2.47 0.14 6 0.02*,# 2.94 6 0.12*,# 8.32 6 0.06*,# 4
Data are means 6 SEM with n representing the number of separate experiments carried out. In each experiment, ROIs were drawn around
the membrane of 10 cells. NA, not applicable. *Statistical signiﬁcance (P, 0.05) from the value determined for 10 nM and #P, 0.05 from 30 nM
BODIPY-TMR-CGP in CHO-b1 cells (1-way ANOVA followed by Tukey’s multiple comparisons test).
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TMR-CGPbinds to the secondary low afﬁnity conformation
of the b1-adrenoceptor, and as such may cause allosteric
effects that result in an enhanced dissociation rate of
100nMBODIPY-TMR-CGP(i.e.,negativecooperativity) from
the primary high-afﬁnityb1-adrenoceptor conformation.
This wasnot evident for 10and30nMBODIPY-TMR-CGP,
which is likely caused by lower occupancy levels of
these BODIPY-TMR-CGP concentrations at the sec-
ondary b1-adrenoceptor conformation compared with
100 nM BODIPY-TMR-CGP (24). The concentration
independence of the dissociation rates of 10 and 30 nM
BODIPY-TMR-CGP and the concentration dependence
of the observed association rates of 10, 30, and 100 nM
BODIPY-TMR-CGP at the b1-adrenoceptor were clearly
seen for normalized grouped data (Fig. 3A, B), as well as
single cell data (Fig. 3C, D). The observed association
(konobs) and b1-adrenoceptor–speciﬁc dissociation rate
(koff(slow)) of each BODIPY-TMR-CGP concentration
wereused todetermine the association rate constants (kon).
The kon and koff(slow) were then used to calculate the
equilibrium dissociation constant (KD) for each BODIPY-
TMR-CGP concentration and are summarized in Table 1.
Cooperative interactions between the high- and low-
afﬁnity conformation of the human b1-adrenoceptor
The dissociation rate of a ligand should not be altered in
the presence of a second ligand if the two compete for the
same binding site. However, if the second ligand binds to
a separate second binding site, a resulting conformational
change could lead to cooperative (allosteric) effects and
thus affect the dissociation rate of the ﬁrst ligand (23,
28–30). To assess whether the faster dissociation rate ob-
served for 100 nM BODIPY-TMR-CGP was in fact caused
by cooperative interactions between the high- and low-
afﬁnity conformation of the b1-adrenoceptor, we inves-
tigated the dissociation rates of 3 nM BODIPY-TMR-CGP
in the absence and presence of increasing concen-
trations of CGP 12177 and propranolol. We previously
showed that 3 nM BODIPY-TMR-CGP predominantly
labels the high-afﬁnity conformation over the secondary
low-afﬁnity conformation of theb1-adrenoceptor [;86%
and 3% occupancy, respectively, based on the afﬁnity of
BODIPY-TMR-CGP for the high- and low-afﬁnity b1-
adrenoceptor conformations determined in functional
assays (24)]. This limits competition of labeled and un-
labeled ligands at the secondary b1-adrenoceptor con-
formation and therefore ensures that any observed
effects on the BODIPY-TMR-CGP dissociation rate are
caused by the unlabeled ligand used.
First, we assessed the association and dissociation kinet-
ics of 3 nM BODIPY-TMR-CGP at CHO-b1 and CHO-CS
cells (Fig. 4). The ﬂuorescence intensities measured in
CHO-CS cells were too low to accurately determine ob-
served association and dissociation rates. In line with this,
the nonspeciﬁc binding component in the 3 nM BODIPY-
TMR-CGP dissociation trace obtained in CHO-b1 cells was
also too low to be detected and therefore was analyzed as
b1-adrenoceptor-speciﬁc dissociation using a 1-phase dis-
sociation equation. This gave a dissociation rate of 0.096
0.01 min21 (n = 9) in the absence of unlabeled ligands,
which was similar to the dissociation rate obtained for 10
and 30 nM BODIPY-TMR-CGP (P . 0.05, 1-way ANOVA
followedbyTukey’smultiplecomparisons test).Toselectively
label the high-afﬁnity conformation of the b1-adrenoceptor,
we chose a concentration of 3 nM BODIPY-TMR-CGP
(24) for subsequent dissociation experiments and lim-
ited the association of ﬂuorescent ligand to 4 min. As
a consequence, the association of 3 nM BODIPY-TMR-
CGP did not reach a plateau within this time period, and
the association rate could not be accurately determined
Figure 3. Association and dissociation kinetics
of 10, 30, and 100 nM BODIPY-TMR-CGP in
CHO-b1 cells. The ﬂuorescence intensity of 10,
30, and 100 nM BODIPY-TMR-CGP (BOD-
CGP) during perfusion of BODIPY-TMR-CGP
(association) and imaging buffer only (dissoci-
ation) was monitored every 3 s (shown for every
6 s for better visualization). A and B) Normal-
ized association (A) and dissociation data (B)
of BODIPY-TMR-CGP (BOD-CGP) in CHO-b1
cells are means 6 SEM of 5, 6, and 4 separate
experiments for 10, 30, and 100 nM BODIPY-
TMR-CGP, respectively. Association data were
normalized to the predicted maximum binding
level of each BODIPY-TMR-CGP concentration
used (determined using a monoexponential
association equation; Eq. 1). Speciﬁc dissociation
data were normalized to the ﬂuorescence in-
tensity level measured before initiation of imag-
ing buffer only perfusion. C and D) Single cell
analysis of observed association rates (C) and
dissociation rate (D) constants for 10, 30, and
100 nM BODIPY-TMR-CGP, with each replicate
representing the kinetic parameter of 1 single
cell. Data shown are means 6 SEM of 50, 60, and 40 separate cells for 10, 30, and 100 nM BODIPY-TMR-CGP, respectively, and
represent the parameter estimates of single cells from 5, 6, and 4 separate experiments for 10, 30, and 100 nM BODIPY-TMR-CGP,
respectively. Summary data and statistical analysis are provided in Table 1.
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from these data alone. However, when globally analyzed in
conjunction with the dissociation trace, an association rate
constant (kon) of 5.27 6 0.53 3 10
7 M21×min21 (n = 9),
a dissociation rate (koff) of 0.086 0.01 min
21 (n = 9), and
a pKD of 8.836 0.06 (n = 9) were obtained (Fig. 4C).
Next, the inﬂuenceof unlabeled ligandson theBODIPY-
TMR-CGP dissociation rate was examined, and the disso-
ciation rate of 3 nM BODIPY-TMR-CGP was signiﬁcantly
enhanced in the presence of 100 nM (0.21 6 0.02 min21,
n = 5), 1mM(0.206 0.02min21, n = 7), and 10mM(0.226
0.03 min21, n = 5) CGP 12177 (P , 0.05, 1-way ANOVA
followed by Dunnett’s multiple comparisons test; Fig. 5A
and Table 2). A similar increase in BODIPY-TMR-CGP dis-
sociation rate was observed in the presence of 1mM(0.196
0.01 min21, n = 6) and 10 mM (0.22 6 0.03 min21, n = 5)
propranolol (Fig. 5B). The effect of the enhanced dis-
sociation rate was concentration dependent and satura-
ble, which is characteristic of allosteric interactions (28).
A concentration-response curve was ﬁtted through the
grouped BODIPY-TMR-CGP dissociation rates (listed in
Table 2) plotted against the concentrations of unlabeled
CGP 12177 (Fig. 5C) and propranolol (Fig. 5D) used, with
the midpoint of the curve providing afﬁnity estimates
(pKD) of the unlabeled ligands for a secondary confor-
mation on the b1-adrenoceptor with the ﬂuorescent
ligand already bound to the primary orthosteric confor-
mation, which were determined to be 7.79 and 6.65 for
CGP 12177 and propranolol, respectively. These values
are consistent with those determined from inhibition of
functional CGP 12177 responses via the secondary con-
formation of the b1-adrenoceptor (11, 24).
Inﬂuence of TM4 on cooperative interactions
involving the b1-adrenoceptor
To further investigate the cooperative effects observed
aboveon theBODIPY-TMR-CGPdissociation rate fromthe
catecholamine conformation by the action of propranolol
and CGP 12177 acting at the secondary conformation, we
examined the effect of CGP 12177 on the BODIPY-TMR-
CGP dissociation kinetics in CHO-b1TM4 cells. These cells
express b1-adrenoceptors that have been mutated such
that the residues in TM4 are those of the b2-adroceptor
(11). Importantly, this mutant b1-adrenceptor does not
exhibit the secondary CGP 12177 conformation (11). In
the absence of unlabeled ligands, the dissociation rate of
3nMBODIPY-TMR-CGP inCHO-b1TM4cellswas 0.0666
0.005 min21 (n = 8) in these cells. Interestingly, the disso-
ciation rates of 3nMBODIPY-TMR-CGP in thepresenceof
1 mM CGP 12177 and 1 mM propranolol were 0.089 6
0.010 (n = 6) and 0.080 6 0.007 min21 (n = 10), res-
pectively, which are comparable to the dissociation rate in
the absenceof ligands (P.0.05, 1-wayANOVAfollowedby
Dunnett’s multiple comparisons test; Fig. 6).
Effects of enhancing and disrupting b1AR homodimer
interactions on cooperative interactions
The cooperative effects observed above at the wild-type
b1-adrenoceptor clearly highlight the presence of 2 dis-
tinct binding conformations to which b-adrenoceptor
ligands can bind. Baker et al. (7) conducted mutagenesis
studies in which selected mutations (e.g., D138A) in
the orthosteric ligand binding domain disrupted both
thehigh-and low-afﬁnitybindingconformation(7).Twokey
mutations in the b1-adrenoceptor TM4 region completely
Figure 4. Association and dissociation kinetics of 3 nM
BODIPY-TMR-CGP in CHO-b1 and CHO-CS cells. A) Confo-
cal images show BODIPY-TMR-CGP (BOD-CGP) binding to
CHO-b1 and CHO-CS cells after 4 min BODIPY-TMR-CGP
association and are representative of 9 and 4 experiments for
CHO-b1 and CHO-CS cells, respectively. Scale bars, 20 mm. B)
Association and dissociation kinetics of 3 nM BODIPY-TMR
measured in CHO-b1 and CHO-CS cells. Data shown are
means 6 SEM of ﬂuorescence intensities of 10 cells measured
every 2 s (shown every 6 s for better visualization) in a single
experiment that is representative of 9 and 4 experiments for
CHO-b1 and CHO-CS cells, respectively. C) Normalized
association and dissociation of 3 nM BODIPY-TMR-CGP at
CHO-b1 cells. Data were normalized to the BODIPY-TMR-
CGP binding level following 4 min association to allow data to
be grouped and are means 6 SEM of 9 separate experiments.
Each experimental replicate reﬂects the average ﬂuorescent
intensity of the plasma membrane of 5–10 single cells.
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abolished the secondary conformation(L195QandW199Y)
(11). Interestingly, these are thought to lie within the
TM4-TM5 heterodimer interface of the b1-adrenoceptor
(19), suggesting a potential role of b1-adrenoceptor
homodimerization in the secondary conformation CGP
12177 pharmacology.
Furthermore, this study showed that the cooperative
interactions at the wild-type b1-adrenoceptor are com-
pletely prevented in CHO-b1TM4 cells (Fig. 6). Homo-
dimerization of b1-adrenoceptors has been reported to be
transient (20, 21). Thus, to detect b1-adrenoceptor homo-
dimers and allow their pharmacological investigation, we
Figure 5. Enhanced dissociation of 3
nM BODIPY-TMR-CGP in CHO-b1
cells in the presence of CGP 12177
and propranolol. 3 nM BODIPY-TMR-
CGP dissociation was monitored un-
der ID conditions every 2 s (shown
every 6 s for better visualization) in
the absence (n = 9) of unlabeled
ligands and in the presence of (A)
10 nM (n = 6), 100 nM (n = 5), 1 mM
(n = 7), and 10 mM (n = 5) CGP 12177
or (B) 100 nM (n = 3), 1 mM (n = 6),
and 10 mM (n = 5) propranolol. Data
were normalized to the ﬂuorescence
intensity level measured before initia-
tion of imaging buffer only perfusion.
The lower panels show the change in
dissociation rate constant (koff) of
3 nM BODIPY-TMR-CGP in the ab-
sence and presence of increasing CGP
12177 (C) or propranolol (D). The
midpoint of the concentration-effect
curves provided the apparent CGP
12177 and propranolol afﬁnities for
the secondary binding site through
which the cooperative effects were
mediated. All data shown are means 6
SEM of indicated n separate experiments.
Each experimental replicate reﬂects the
average ﬂuorescent intensity of the plasma membrane of 5–10 cells. *Statistical signiﬁcance (P , 0.05) from control conditions (ID) as
determined by 1-way ANOVA followed by Dunnett’s multiple comparisons test.
TABLE 2. Dissociation rate constants of 3 nM BODIPY-TMR-CGP in the absence and presence of CGP
12177 and propranolol
Condition
CGP 12177 Propranolol
koff (min
21) n koff (min
21) n
CHO-b1
Inﬁnite dilution 0.09 6 0.01 9 0.09 6 0.01 9
+10 nM 0.13 6 0.02 6 ND
+100 nM 0.21 6 0.02* 5 0.13 6 0.03 3
+1 mM 0.20 6 0.02* 7 0.19 6 0.01* 6
+10 mM 0.22 6 0.03* 5 0.22 6 0.03* 5
CHO-b1TM4
Inﬁnite dilution 0.07 6 0.02 8 0.07 6 0.02 8
+1 mM 0.09 6 0.01# 6 0.08 6 0.02# 10
CHO-b1YFPN/b1YFPC
Inﬁnite dilution 0.02 6 0.01# 5 0.02 6 0.01# 5
+1 mM 0.19 6 0.01#,@ 6 0.19 6 0.01#,@ 6
CHO-b1YFPN/b1D138AYFPC
Inﬁnite dilution 0.05 6 0.01 5 0.05 6 0.01 5
+1 mM 0.17 6 0.01#,@ 4 0.14 6 0.01#,@ 5
Data are means 6 SEM of n separate experiments. ND, not determined. *Statistical signiﬁcance
(P , 0.05) in CHO-b1 cells from control conditions (inﬁnite dilution) for each unlabeled ligand used
(1-way ANOVA followed by Dunnett’s multiple comparisons test). #Statistical signiﬁcance (P , 0.05)
from the equivalent value in CHO-b1 cells and
@P , 0.05 from control conditions (inﬁnite dilution)
within each cell line (2-way ANOVA followed by Tukey’s multiple comparisons test).
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used BiFC (31, 32) to irreversibly trap and stabilize b1-
adrenoceptor homodimers that formed at any given time.
We hypothesized that constraining dimers using BiFC
would increase the percentage ofb1-adrenoceptors dimers
and as such enhance any dimer-mediated allosteric effects.
It has been shownpreviously that aD138Amutation inTM3
disrupted ligand binding to both the catecholamine and
the secondary conformation of the b-adrenoceptor (7).
Consequently, any enhanced allosteric effects should be
prevented by constraining dimers containing 1 nonligand-
binding protomer (b1D138A) (7).
BiFC uses 2 nonﬂuorescent fragments of a ﬂuorescent
protein, which reconstitute the functional (i.e., ﬂuores-
cent) full-length ﬂuorescent protein when in close prox-
imity to one another (32). The N-terminal fragment and
the C-terminal fragment of the YFP (YFPN and YFPC, re-
spectively) were fused to the C-terminal end of the wild-
type or D138A b1-adrenoceptor to generate the b1YFPN,
b1YFPC, and b1D138AYFPC receptor constructs. The
b1YFPN/b1YFPC and b1YFPN/b1D138AYFPC constructs
were transiently cotransfected into CHO-K1 cells, and
clear membrane ﬂuorescence of reconstituted YFP and
BODIPY-TMR-CGP binding could be seen (Fig. 7), con-
ﬁrming cell surface expression of wild-type/wild-type and
wild-type/D138A b1-adrenoceptor homodimers that each
contain at least 1 BODIPY-TMR-CGP binding conforma-
tion.Toconﬁrm that theD138Amutationabolished ligand
binding to the b1-adrenoceptor, we examined the binding
of 3 nM BODIPY-TMR-CGP to a SNAP-tagged D138A b1-
adrenoceptor. Indeed, no binding of 3 nMBODIPY-TMR-
CGP could be seen inCHO-K1 cells transiently transfected
with the SNAP-b1D138A construct, but clear membrane
ﬂuorescence was observed following labeling of the SNAP-
tag with 1 mM BG-488, conﬁrming the expression of the
non–ligand-binding receptor at the cell surface (Fig. 8,
lower leftpanel).ASNAP-taggedwild-typeb1-adrenoceptor
was transiently transfected as a positive control, and clear
ﬂuorescence of the BG-488 labeled SNAP-tag and 3 nM
BODIPY-TMR-CGPbinding to the wild-type receptor can
be seen (Fig. 8, upper panel). This indicates that the lack
of BODIPY-TMR-CGP ﬂuorescence seen for the SNAP-
b1D138A–transfected cells is caused by the D138A muta-
tion introduced into the b1-adrenoceptor.
We then examined the dissociation rate of 3 nM
BODIPY-TMR-CGP at irreversibly constrained stable
wild-type/wild-type b1-adrenoceptor homodimers under
ID conditions, which was determined to be 0.02 6 0.01
min21 (n = 5; Fig. 9A). This was signiﬁcantly slower than
the dissociation ratemeasured inCHO-b1 cells (P, 0.05,
2-way ANOVA analysis followed by Tukey’s multiple
comparisons test). The dissociation of 3 nM BODIPY-
TMR-CGPbindingwas enhanced in thepresenceof 1mM
CGP 12177 and 1 mMpropranolol with dissociation rates
of 0.1866 0.008 (n = 6) and 0.1896 0.007min21 (n = 6),
respectively (Fig. 9A). This was signiﬁcantly faster than
the dissociation rate determined in the absence of un-
labeled ligands (P , 0.05, 2-way ANOVA followed by
Tukey’s multiple comparisons test; Fig. 9A). The change
in the 3 nM BODIPY-TMR-CGP dissociation rate in the
absence and presence of unlabeled ligands was ;2-fold
in CHO-b1 cells but was ;10-fold in CHO-K1 cells
expressing b1YFPN/b1YFPC homodimers.
The transient expression of BiFC constructs yielded
amixed population of cells with different expression levels
Figure 6. Role of TM4 of the b1-adrenoceptor in the
observation of cooperative interactions between BODIPY-
TMR-CGP and CGP 12177 and propranolol. Dissociation of
3 nM BODIPY-TMR-CGP was measured under inﬁnite dilution
conditions every 2 s (shown every 6 s for better visualization) in
CHO-b1TM4 cells stably expressing b1-adrenoceptors in
which its native TM4 region was mutated to be the TM4 region
of the b2-adrenoceptor. A) Normalized 3 nM BODIPY-TMR-
CGP dissociation in the absence (n = 8) and presence of 1 mM
CGP 12177 (n = 6) or 1 mM propranolol (n = 10), with data
shown as means6 SEM of the indicated n separate experiments.
Each experimental replicate reﬂects the average ﬂuorescent
intensity of the plasma membrane of 3–6 single cells within
a single experiment. Data were normalized to the ﬂuorescence
intensity level measured before initiation of imaging buffer only
perfusion. B) Single cell dissociation rate constants (koff) for
3 nM BODIPY-TMR-CGP under inﬁnite dilution conditions in
the absence (ID; n = 33) and presence of 1 mM CGP 12177
(CGP; n = 24) and 1 mM propranolol (prop; n = 36), with each n
representing the number of individual cells measured. Solid
lines show the means 6 SEM of indicated number of single cells
obtained from 8 (ID), 6 (CGP 12177), and 10 (propranolol)
separate experiments.
Figure 7. Cell surface expression of BiFC-constrained b1-
adrenoceptor homodimers. Confocal images show binding
of 3 nM BODIPY-TMR-CGP following 4-min association to
CHO-K1 cells transiently expressing BiFC-constrained wild-
type b1-adrenoceptor homodimers (b1YFPN/b1YFPC; upper
panel) and BiFC-constrained b1-adrenoceptor homodimers
containing 1 wild-type and 1 nonligand-binding protomer
(b1YFPN/b1D138AYFPC; lower panel). The ﬂuorescence of the
complimented YFP was measured simultaneously to conﬁrm
the cell surface expression of b1-adrenoceptor homodimers.
Images are representative of 5 separate experiments. Scale
bars, 50 mm. The binding of BODIPY-TMR-CGP in the lower
right conﬁrms that the b1YFPN/b1D138AYFPC dimer pairs
contain a viable single orthosteric binding site.
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(Fig. 7 and Supplemental Fig. S1). To investigate whether
higher expression levels of b1-adrenoceptor homodimers
affected the BODIPY-TMR-CGP dissociation rate mea-
surements in this study, we compared the measurements
taken in cells with both high and low expression levels
(Supplemental Fig. S1). These data conﬁrmed that the
dissociation kinetics were very similar at both expression
levels (Supplemental Fig. S1).
The dissociation rate of 3 nM BODIPY-TMR-CGP in
CHO-K1 cells transiently transfected with 1 wild-type
and 1 nonligand-binding b1-adrenoceptor construct
(b1YFPN/b1D138AYFPC) under ID conditions was de-
termined to be 0.054 6 0.011 min21 (n = 5). This dis-
sociation rate was increased in the presence of 1 mM
CGP 12177 (koff, 0.1696 0.010 min
21; n = 6) and 1 mM
propranolol (koff, 0.1446 0.009 min
21; n = 5; P, 0.05,
2-way ANOVA followed by Tukey’smultiple comparisons
test; Fig. 9B). Interestingly, the difference in the 3 nM
BODIPY-TMR-CGP dissociation rate in the presence of
unlabeled ligands compared with in the absence of
unlabeled ligands was ;3-fold in cells expressing con-
strained wild-type/nonligand-binding b1-adrenoceptor
homodimers.
DISCUSSION
In this study, we used a confocal microscopy approach in
conjunction with a perfusion system to investigate the dis-
sociation kinetics of BODIPY-TMR-CGP from the human
b1-adrenoceptor under ID conditions in single living cells.
Using this technique, we revealed negative cooperative
Figure 8. Cell surface expression of the
nonligand-binding b1D138A-adrenoceptor. The
cell surface expression of SNAP-tagged wild-type
(SNAP-b1; upper panel) and nonligand-binding
(SNAP-b1D138A; lower panel) b1-adrenoceptor
was visualized following labeling of the SNAP-tag
with 1 mM BG-488 (30 min, 37°C). The ligand-
binding properties of the SNAP-tagged wild-
type and nonligand-binding receptors were
examined by exposing the cells to 3 nM
BODIPY-TMR-CGP (10 min, 37°C). The
merged images highlight colocalization of cell
surface SNAP-tagged b1-adrenoceptors (green)
and BODIPY-TMR-CGP (BOD-CGP) binding
(red) to these receptors in yellow pixels. The
images are representative of 3 different ﬁelds of
view imaged on 3 separate experimental days.
Scale bars, 20 mm.
Figure 9. Cooperative interactions be-
tweenBODIPY-TMR-CGPandCGP12177
and propranolol in bimolecular ﬂuores-
cence complementation-constrained b1-
adrenoceptordimers.Dissociationof3nM
BODIPY-TMR-CGP was measured un-
der IDconditionsevery2s(shownevery
6 s for better visualization). A) Normal-
ized dissociation of 3 nM BODIPY-
TMR-CGP in CHO-K1 cells transiently
expressingwild-type (b1YFPN/b1YFPC)
BiFC-constrainedb1-adrenoceptorhomo-
dimersunderIDconditionsintheabsence
(n=5)andpresenceof1mMCGP12177
(n = 6) and 1mMpropranolol (n = 6). B)
Normalizeddissociationof3nMBODIPY-
TMR-CGP in CHO-K1 cells transiently
expressing1wild-typeand1nonligand-
binding (b1YFPN/b1D138AYFPC) proto-
merinBiFC-constrainedb1-adrenoceptor
homodimers under ID conditions in
the absence (n = 5) and presence of
1 mM CGP 12177 (n = 6) and 1 mM
propranolol (n = 5). Data were normal-
ized to the ﬂuorescence intensity level measured before initiation of imaging buffer only perfusion and show means 6 SEM of the
indicated n separate experiments. Each experimental replicate reﬂects the averageﬂuorescent intensity of the plasmamembrane of
10 cells.
2868 Vol. 29 July 2015 GHERBI ET AL.The FASEB Journal x www.fasebj.org
interactions between the high- and low-afﬁnity b1-
adrenoceptor conformations, which are facilitated by
b1-adrenoceptor homodimerization.
In CHO-b1 cells, the observed association rates for
10, 30, and 100 nM BODIPY-TMR-CGP increased in
a concentration-dependentmanner. The dissociation rate
wasmonophasic for 10nMﬂuorescent ligand, but biphasic
for higher concentrations (30 and 100 nM) of BODIPY-
TMR-CGP. The fast dissociation component was clearly
identiﬁedasanonspeciﬁc componentas itwas comparable
to the dissociation rate observed in CHO-CS cells lacking
the b1-adrenoceptor. The b1-adrenoceptor–speciﬁc dis-
sociation rates were comparable for 10 and 30 nM
BODIPY-TMR-CGP, but not for 100 nM BODIPY-TMR-
CGP, where a signiﬁcantly faster dissociation rate was ob-
served. According to classic receptor theory, dissociation
rates of a ligand should be independent of the ligand
concentration used. However, this analysis assumes that
the ligand only binds to 1 receptor binding conformation
(25).We recently describedBODIPY-TMR-CGPbinding to
both the high- and low-afﬁnity conformations of the hu-
manb1-adrenoceptor with afﬁnity values of 0.6 and 87 nM,
respectively (24). Thus, the observation of a faster dissoci-
ation rate for 100nMBODIPY-TMR-CGPmaybe causedby
BODIPY-TMR-CGP binding to both the high- and low-
afﬁnity b1-adrenoceptor conformations andmay be a con-
sequence of negative cooperativity occurring between
these 2 ligand-bound conformations.
To further explore the potential for negative co-
operativity between different conformations within the b1-
adrenoceptor, we examined the dissociation rate of 3 nM
BODIPY-TMR-CGP in the absence and presence of in-
creasing concentrations of unlabeled ligands. The afﬁnity
value derived from the association and dissociation param-
eters obtained for 3 nM BODIPY-TMR-CGP (;2.6 nM)
compared well to the afﬁnity value of BODIPY-TMR-CGP
for the orthosteric binding conformation determined in
functional studies (0.6 nM) (24). This strongly suggests
that 3 nM BODIPY-TMR-CGP predominantly binds the
high-afﬁnity b1-adrenoceptor conformation. This there-
fore allows potential cooperative effects exerted by un-
labeled ligands binding to a secondary conformation to be
measured. The dissociation rate of a labeled ligand should
remain unchanged in the presence of an unlabeled ligand
that binds to the same receptor site (28). Therefore, any
changes of the dissociation rate of 3 nM BODIPY-TMR-
CGP from thehigh-afﬁnityb1-adrenoceptor conformation
would be caused by the unlabeled b-adrenoceptor ligands
CGP 12177 and propranolol binding to a topographically
distinct (allosteric) binding conformation that exerts a co-
operative effect on the high-afﬁnity (orthosteric) confor-
mation. Indeed, the BODIPY-TMR-CGP dissociation rate
was enhancedby100nMCGP12177andpropranolol (and
concentrations above), clearly highlighting the presence
of a secondary topographically distinct b1-adrenoceptor
binding conformation through which CGP 12177 and
propranolol exert negative cooperative effects on the pri-
mary high-afﬁnity b1-adrenoceptor conformation. The
apparent dissociation constants (KD) of CGP 12177 and
propranolol for this secondary (allosteric) conformation
could be determined from the concentration dependence
of the cooperative effect of each ligand on the BODIPY-
TMR-CGP dissociation rates. These were similar to those
values determined for these ligands for the low-afﬁnity b1-
adrenoceptor conformation in previous functional studies
(24). This allosteric conformation could therefore be re-
sponsible for the secondary low-afﬁnity CGP 12177 b1-
adrenoceptor conformation.
A previous mutagenesis study by Baker et al. (7)
reported that the 2 b1-adrenoceptor conformations
must overlap to some degree, as the introduction of
certain single point mutations (e.g., D138A) in the b1-
adrenoceptor affected both conformations. However,
Baker et al. (11) recently identiﬁed key residues in TM4
that only affect the pharmacology of the secondary
low-afﬁnity b1-adrenoceptor conformation, leaving
the catecholamine conformation unaffected. The
same mutations in TM4 also removed the cooperative
effect observed in this study (Fig. 6).
Furthermore, this clearly highlights that the BODIPY-
TMR-CGPdissociationkineticsmeasured in this studywere
not inﬂuenced by rebinding of the ﬂuorescent ligand
to unoccupied b1-adrenoceptors on neighboring cells.
Rebinding can potentially result in a slowed dissociation
rate of the labeled ligand, which is then increased in the
presence of a high concentration of a competing ligand
that prevents rebinding of the labeled ligand (33, 34). In
this study, the rapidﬂuid exchange of the perfusion system
was used to prevent the reassociation of the ﬂuorescent
ligand (27). Most convincingly, however, high concen-
trations of unlabeled CGP 12177 and propranolol that in
CHO-b1TM4 cells are strictly competitive toBODIPY-TMR-
CGP binding did not cause an increased dissociation rate
of BODIPY-TMR-CGP.
The TM4 has been highlighted to play a role in di-
merization of various class A GPCRs (35), including the
b1-adrenoceptor (19, 36), indicating a potential role of
b1-adrenoceptor homodimerization in the secondary
conformation. Homodimers of b1-adrenoceptors have
been reported to be transient in nature (20). In an at-
tempt to generate more stable b1-adrenoceptor dimers,
we used a BiFC approach to lock b1-adrenoceptor
homodimers into constrained stable dimers of deﬁned
composition. Although BiFC does not affect the rate of
homodimerization (26), the prevention of dimer disso-
ciation as a consequence of the irreversible nature of
BiFC will increase the percentage of b1-adrenoceptors
that exist as homodimers. The successful trapping of
BiFC-constrained b1-adrenoceptor dimers was demon-
strated in CHO cells cotransfected with YFPN and YFPC-
tagged b1-adrenoceptor constructs by the clear membrane
labeling observed with the reconstituted YFP. In cells
expressing these wild-type (b1YFPN/b1YFPC) BiFC-
constrained b1-adrenoceptor homodimers, the BODIPY-
TMR-CGP dissociation rate was enhanced ;10-fold by
1 mM CGP 12177 and 1 mM propranolol. In contrast, only
a ;3-fold difference in dissociation rate was observed in
CHO-b1 cells (i.e., transient unconstrained dimers), sug-
gesting that the cooperative effects of unlabeled ligands
on the dissociation rate of BODIPY-TMR-CGP may be me-
diated across a b1-adrenoceptor homodimer interface
(Fig. 10A). It was also notable that the dissociation of
3 nM BODIPY-TMR-CGP from native transient b1-
adrenoceptor dimers (koff, 0.09 min
21) was faster than
that from wild-type BiFC-constrained b1-adrenoceptor
homodimers (koff, 0.02 min
21). This suggests that the
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formation of stable homodimers itself leads to signiﬁcant
basal allosteric inﬂuences on ligand binding kinetics.
To further test whether the secondary (allosteric) b1-
adrenoceptor conformation is facilitated by a second
b1-adrenoceptor protomer in a homodimer complex,
BODIPY-TMR-CGP dissociation kinetics were determined
in cells expressing BiFC-constrained b1-adrenoceptor
homodimers of 1 wild-typeb1-adrenoceptor (b1YFPN) and
1 protomer containing a point mutation that abolished
binding of b-adrenoceptor ligands at both the primary
catecholamineandsecondary conformations (b1D138AYFPC)
(7). The removal of one of the orthosteric binding con-
formations in a homodimeric b-adrenoceptor pair should
remove thepotential fornegatively cooperative affects across
the dimer interface (Fig. 10B). Indeed, in cells expressing
b1YFPN/b1D138AYFPC BiFC-constrained homodimers, the
effects ofCGP12177 andpropranolol on theBODIPY-TMR-
CGP dissociation kinetics were reduced and reﬂected more
closely the pharmacology observed in CHO-b1 cells (i.e.,
transient wild-type unconstrained dimers). This residual
cooperativity is most likely caused by the cooperative effects
that can still occur across transientwild-typeb1YFPN/b1YFPN
dimers that will be present in the cell population. Two
dimerization interfaces have been reported for the b1-
adrenoceptor involving transmembrane regions 1 and 2
and helix 8 (TM1/TM2/H8) in the ﬁrst interface and
transmembrane region 4 and 5 and intracellular loop 2
(TM4/TM5/ICL2) in the second interface, the latter of
which has been described to make structural rearrange-
ments during receptor activation (19). Key residues (L195,
W199) identiﬁed byBaker et al. (11) that are responsible for
the secondary conformation lie within the dimer interface
region of TM4. Using a stable cell line containing the
reported b1-adrenoceptor TM4 mutations that result in no
secondary conformation (11),weobservednoeffects on the
dissociation rate of 3 nM BODIPY-TMR-CGP in the pres-
enceof 1mMCGP12177and1mMpropranolol.The loss of
the enhanced dissociation rate in cells expressing b1-
adrenoceptor TM4 mutations is consistent with a role of
a dimerization interface involving TM4 in the negative
cooperativity observed at the b1-adrenoceptor (Fig. 10C).
In summary, these data suggest that the secondary
low-afﬁnity conformation of the b1-adrenoceptor may
be a consequence of negative cooperative interactions be-
tween 2 orthosteric binding conformations within a b1-
adrenoceptor homodimer. This can then lead to a reduced
apparent afﬁnity of ligands for the second protomer of an
already ligand-occupied (on theﬁrst protomer) dimer [see
Supplemental Fig. S1 in May et al. (23)]. The contribution
of these cooperative interactions is provided by the coop-
erativity factor a, and the ligand afﬁnity for the already
ligand-bound receptor is described as a ratio of the ligand
afﬁnity for the unbound receptor and the cooperativity
factor a (KB/a). As such, the cooperativity factor at b1-
adrenoceptordimers canbedeterminedby taking the ratio
of the apparentKD valuedetermined for binding to theﬁrst
protomer (orthosteric b1-adrenoceptor conformation 1
KD, i.e., unbound receptor) and that determined for mod-
ifying the dissociation rate of BODIPY-TMR-CGP from
conformation 1 by an unlabeled ligand binding to the
second protomer (allosteric b1-adrenoceptor conforma-
tion 2 KD, i.e., ligand-bound receptor). Negative coopera-
tivity that leads to an increase in the apparent dissociation
observed is reﬂected in a cooperativity factor smaller than
unity. Indeed, the cooperativity factors (a) for CGP 12177
and propranolol were estimated to be 0.015 and 0.010, re-
spectively, using thebindingafﬁnities for theorthostericb1-
adrenoceptor conformation determined in Gherbi et al.
(24). A mechanistic framework for the secondary b1-
adrenoceptor conformation based on homodimer for-
mation opens up new insights into the role of dimerization
in altering the molecular pharmacology of GPCRs.
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